Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Impact · against what's priced in

The article confirms existing acquisition terms for CRNX and APGE, providing no new catalyst for their prices. NUVL receives a positive valuation bump from the confirmation of its $10.6 billion acquisition by GSK.

APGE+0.00

Already priced in

The price assumes

The all-cash acquisition of Apogee by AbbVie at $135.11 per share

The report of AbbVie's $10.9 billion deal for Apogee's pipeline matches the acquisition price the market is already paying for.